Neurocrine Biosciences Inc vs Roundhill NVDA WeeklyPay ETF — how do they compare? Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B), while Roundhill NVDA WeeklyPay ETF trades at $37.17 (market cap $119.10M). The key difference: Neurocrine Biosciences Inc is far larger — about 120.6× Roundhill NVDA WeeklyPay ETF's market cap, and Roundhill NVDA WeeklyPay ETF is more actively traded (44,838 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Roundhill NVDA WeeklyPay ETF for 50 Days on average.
| NBIX | NVDW | |
|---|---|---|
Market Cap | $14.36B | $119.10M |
Volume | 1,237,180 | 44,838 |
Sector | Health | Income / Options Overlay |
52-Week High | $185.50 | $52.33 |
52-Week Low | $123.10 | $31.88 |
Typical Hold Time | 23 Days | 50 Days |
Enterprise Value | $14.37B | — |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →